Endometriosis therapy - Bayer/Evotec

Alternative Names: Second endometriosis candidate - Bayer/Evotec

Latest Information Update: 10 Aug 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Bayer; Evotec AG
Class Analgesics; Anti-inflammatories
Mechanism of Action Inflammation mediator modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Endometriosis

Most Recent Events

24 Jul 2017 Phase-I clinical trials in Endometriosis in Germany (unspecified route)
24 Jul 2017 Evotec and Bayer extend collaboration for Endometriosis therapeutics until 2018

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.